截至9月30日，上海凯宝股东户数4.93万，较上期减少6.04%；人均流通股18586股，较上期增加6.43%。 2025年1月-9月，上海凯宝实现营业收入8.19亿元，同比减少26.95%；归母净利润1.87亿元，同比减少 13.83%。 分红方面，上海凯宝A股上市后累计派现15.53亿元。近三年，累计派现3.03亿元。 机构持仓方面，截止2025年9月30日，上海凯宝十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股699.22万股，相比上期增加75.01万股。南方中证1000ETF（512100）位居第六大流通股 东，持股574.45万股，相比上期减少20.08万股。汇添富中证中药ETF（560080）位居第七大流通股东， 持股390.98万股，相比上期增加101.73万股。华夏中证1000ETF（159845）位居第八大流通股东，持股 341.02万股，相比上期减少5500.00股。广发中证1000ETF（560010）退出十大流通股东之列。 11月26日，上海凯宝盘中上涨2.03%，截至10:02，报6.54元/股，成交9766.61万元，换手率1.64%，总市 值68.41亿元。 资金 ...

Core Viewpoint - Yiling Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 24.44%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders reached 1 billion yuan, reflecting a substantial year-on-year growth of 80.33% [2]. Stock Market Activity - As of November 26, Yiling Pharmaceutical's stock price was 19.55 yuan per share, with a trading volume of 4.24 billion yuan and a market capitalization of 32.662 billion yuan. The stock has experienced a 3.66% increase over the past five trading days and a 20.83% increase over the past 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 64.05 million yuan on January 6, contributing to a total buy of 233 million yuan, which accounted for 14.28% of total trading volume [1]. Shareholder Information - As of September 30, 2025, Yiling Pharmaceutical had 152,700 shareholders, a decrease of 10.22% from the previous period. The average number of circulating shares per shareholder increased by 11.38% to 9,013 shares [2]. - The company has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest shareholder with 25.704 million shares, an increase of 8.1119 million shares from the previous period. Meanwhile, the Southern CSI 500 ETF has reduced its holdings by 256,900 shares [3].

11月25日，明德生物盘中上涨2.02%，截至11:14，报19.23元/股，成交1742.75万元，换手率0.58%，总 市值44.71亿元。 资金流向方面，主力资金净流出18.98万元，特大单买入0.00元，占比0.00%，卖出134.42万元，占比 7.71%；大单买入208.37万元，占比11.96%，卖出92.93万元，占比5.33%。 明德生物今年以来股价涨11.37%，近5个交易日跌1.99%，近20日跌1.03%，近60日跌10.68%。 资料显示，武汉明德生物科技股份有限公司位于湖北省武汉市东湖新技术开发区九龙中路77号，成立日 期2008年1月28日，上市日期2018年7月10日，公司主营业务涉及体外诊断试剂和诊断仪器的研发、生 产、销售和服务。主营业务收入构成为：体外诊断产品和解决方案65.04%，第三方医学检验21.91%， 代理业务及其他13.05%。 明德生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：禽流感药物、辅助生 殖、体外诊断、宠物经济、猴痘概念等。 截至11月20日，明德生物股东户数2.34万，较上期增加0.11%；人均流通股6660股，较上期减少0. ...

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 18.936 billion yuan, despite an overall increase of 86.44% year-to-date [1] Financial Performance - For the period from January to September 2025, Zhongsheng Pharmaceutical reported a revenue of 1.889 billion yuan, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.40% to 251 million yuan [2] - The company has cumulatively distributed 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Stock Market Activity - The stock has seen significant trading activity, with a net outflow of 67.267 million yuan in major funds recently, and it has appeared on the trading leaderboard seven times this year [1] - The stock price has fluctuated, with a recent 5-day decline of 5.75% and a 20-day increase of 20.89% [1] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 18.90% to 72,900, while the average number of circulating shares per person increased by 23.31% to 10,445 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited and several funds from Xingquan, indicating a mix of new and increasing positions among major shareholders [3]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

11月19日，康缘药业盘中下跌2.06%，截至13:18，报15.20元/股，成交8470.28万元，换手率0.97%，总 市值86.06亿元。 资金流向方面，主力资金净流出643.92万元，大单买入1109.59万元，占比13.10%，卖出1753.51万元， 占比20.70%。 截至9月30日，康缘药业股东户数4.05万，较上期增加17.20%；人均流通股13969股，较上期减少 14.68%。2025年1月-9月，康缘药业实现营业收入23.43亿元，同比减少24.66%；归母净利润2.00亿元， 同比减少44.10%。 责任编辑：小浪快报 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。主营业务收入 构成为：口服类58.68%，注射类33.28%，外用类8.04%。 康缘药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、禽流感药物、医药电 商、抗流感、小盘等。 分红方面，康缘药业A股上市后累计派现9.48亿元。近三年，累计派现3.45亿元。 机构持仓方 ...

Core Viewpoint - Lu Kang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 7.76%, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, Lu Kang Pharmaceutical reported a revenue of 4.624 billion yuan, a year-on-year decrease of 0.91%, and a net profit attributable to shareholders of 141 million yuan, down 59.32% year-on-year [2]. - The company has cumulatively distributed 693 million yuan in dividends since its A-share listing, with 248 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 19, Lu Kang Pharmaceutical's stock price was 10.17 yuan per share, with a total market capitalization of 9.139 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on April 2, where it recorded a net buy of -648.76 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 8.54% to 113,500, while the average number of tradable shares per person increased by 9.33% to 7,915 shares [2]. - Among the top ten circulating shareholders, the Southern CSI 1000 ETF held 6.5781 million shares, a decrease of 84,600 shares compared to the previous period [3].

以岭药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、医药电商、禽流感 药物、幽门螺杆概念、中药等。 截至9月30日，以岭药业股东户数15.27万，较上期减少10.22%；人均流通股9013股，较上期增加 11.38%。2025年1月-9月，以岭药业实现营业收入58.68亿元，同比减少7.82%；归母净利润10.00亿元， 同比增长80.33%。 分红方面，以岭药业A股上市后累计派现44.55亿元。近三年，累计派现18.38亿元。 11月18日，以岭药业盘中下跌2.01%，截至09:58，报19.51元/股，成交3.47亿元，换手率1.28%，总市值 325.95亿元。 资金流向方面，主力资金净流出3907.66万元，特大单买入966.15万元，占比2.79%，卖出2662.36万元， 占比7.68%；大单买入6332.97万元，占比18.27%，卖出8544.41万元，占比24.65%。 以岭药业今年以来股价涨24.19%，近5个交易日跌4.69%，近20日涨13.89%，近60日涨23.25%。 今年以来以岭药业已经1次登上龙虎榜，最近一次登上龙虎榜为1月6日，当日龙虎榜净买入640 ...

11月17日，康缘药业盘中下跌2.01%，截至09:49，报16.06元/股，成交9313.95万元，换手率1.01%，总 市值90.93亿元。 资金流向方面，主力资金净流出248.13万元，特大单买入693.95万元，占比7.45%，卖出661.12万元，占 比7.10%；大单买入1504.77万元，占比16.16%，卖出1785.73万元，占比19.17%。 康缘药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、禽流感药物、医药电 商、抗流感、证金汇金等。 截至9月30日，康缘药业股东户数4.05万，较上期增加17.20%；人均流通股13969股，较上期减少 14.68%。2025年1月-9月，康缘药业实现营业收入23.43亿元，同比减少24.66%；归母净利润2.00亿元， 同比减少44.10%。 康缘药业今年以来股价涨17.91%，近5个交易日涨1.90%，近20日涨3.81%，近60日跌9.01%。 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。 ...

Group 1 - The core viewpoint of the news is that 佛慈制药 has shown a positive stock performance with a year-to-date increase of 23.77% and a recent rise in trading activity, indicating potential investor interest [1][2] - As of November 14, 佛慈制药's stock price reached 9.54 yuan per share, with a market capitalization of 4.872 billion yuan and a trading volume of 44.068 million yuan [1] - The company has experienced net inflows of 834,100 yuan from major funds, with significant buying and selling activity noted in recent trading sessions [1] Group 2 - 佛慈制药's main business includes the research, production, and sales of traditional Chinese medicine, health products, and medical devices, with 99.41% of its revenue coming from these areas [1] - As of September 30, the number of shareholders increased by 8.23% to 33,300, while the average circulating shares per person decreased by 7.61% to 15,340 shares [2] - For the period from January to September 2025, 佛慈制药 reported a revenue of 624 million yuan, a year-on-year decrease of 11.92%, and a net profit attributable to shareholders of 38.0824 million yuan, down 2.54% year-on-year [2] Group 3 - 佛慈制药 has distributed a total of 180 million yuan in dividends since its A-share listing, with 46.9804 million yuan distributed over the past three years [3]